Dll3 modulators and methods of use

Disclosed is an antibody comprising three complementarity determining regions of a light chain variable region set forth as SEQ ID NO: 84, and three complementarity determining regions of a heavy chain variable region set forth as SEQ ID NO: 85, wherein the sequences are as defined in the complete s...

Full description

Saved in:
Bibliographic Details
Main Authors Dylla Scott J, Saunders Laura, Foord Orit, Stull Robert A, Torgov Michael, Shao Hui, Liu David
Format Patent
LanguageEnglish
Published 25.08.2017
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed is an antibody comprising three complementarity determining regions of a light chain variable region set forth as SEQ ID NO: 84, and three complementarity determining regions of a heavy chain variable region set forth as SEQ ID NO: 85, wherein the sequences are as defined in the complete specification. Also disclosed is an antibody drug conjugate of the formula M-[L-D]n, or a pharmaceutically acceptable salt thereof wherein: a) M comprises an anti-DLL3 antibody comprising three complementarity determining regions of a light chain variable region set forth as SEQ ID NO: 84, and three complementarity determining regions of a heavy chain variable region set forth as SEQ ID NO: 85; b) L comprises an optional linker; c) D comprises a cytotoxic agent; and d) n is an integer from 1 to 20. Further disclosed is the use of said antibody drug conjugate in the preparation of a medicament useful in the treatment of cancer.
Bibliography:Application Number: NZ20130628804